dihydroisoxazole (R,R) | 58873-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: dihydroisoxazole (R,R)
• 英文别名: 2,3-dihydroisoxazole；dihydro-isoxazole；Dihydroisoxazole；2,3-dihydro-1,2-oxazole
• CAS: 58873-22-6
• 化学式: C₃H₅NO
• 分子量: 71.0788
• InChiKey: FJRPOHLDJUJARI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  dihydroisoxazole (R,R) 在 氯化亚砜 作用下， 生成 3-[(1R, 5R)-3-azabicyclo[3.1.0]hexan-5-yl]-5-(trifluoromethyl)isoxazole
  参考文献：
  名称：

  Scalable process for the preparation of a GlyT-1 Inhibitor

  摘要：

  This invention relates to a synthetic method for the preparation of Compound 1 and precursors thereof. Compound 1 is prepared via reaction of isoxazole 2 with phenylether (R)-3-ONa.

  公开号：

  US20240083889A1

文献信息

• Isoxazolines as inhibitors of fatty acid amide hydrolase
  申请人：Behnke Mark L.

  公开号：US09149465B2

  公开（公告）日：2015-10-06

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了公式(I)的异噁唑烷FAAH抑制剂或其药学上可接受的形式，其中G、Ra、Rb、Rc和Rd在此定义。本发明还提供了含有公式(I)化合物或其药学上可接受的形式和药学上可接受的赋形剂的制药组合物。本发明还提供了治疗FAAH介导的疾病的方法，包括向需要治疗的受体中给予公式(I)化合物或其药学上可接受的形式的治疗有效量。
• ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Behnke Mark L.

  公开号：US20110028478A1

  公开（公告）日：2011-02-03

  The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, R a , R b , R c , and R d are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.

  本发明提供了式(I)的异噁唑烷FAAH抑制剂或其药学上可接受的形式，其中G、Ra、Rb、Rc和Rd的定义如本文所述。本发明还提供了包括式(I)化合物或其药学上可接受的形式和药学上可接受的赋形剂的制药组合物。本发明还提供了治疗FAAH介导的疾病的方法，包括向需要治疗的患者施用式(I)化合物或其药学上可接受的形式的治疗有效量。
• Scalable process for the preparation of a GlyT-1 Inhibitor
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20240083889A1

  公开（公告）日：2024-03-14

  This invention relates to a synthetic method for the preparation of Compound 1 and precursors thereof. Compound 1 is prepared via reaction of isoxazole 2 with phenylether (R)-3-ONa.